Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January
January 04 2021 - 8:00AM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the discovery, development and commercialization
of innovative therapies for diseases of the eye, today announced
that it will participate in two investor conferences in
January.
Mark Iwicki, Chairman and Chief Executive Officer of Kala
Pharmaceuticals, is scheduled to present at the 39th Annual J.P.
Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10
a.m. ET.
Additionally, Mr. Iwicki will participate in a pre-recorded
fireside chat as part of the H.C. Wainwright BioConnect Conference,
which will be available on the Kala website beginning Monday,
January 11, 2021 at 6:00 a.m. ET.
To access the webcasts and subsequent archived recording of each
presentation, please visit “Events” in the “Investors” section of
the Kala website at http://kalarx.com
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery,
development, and commercialization of innovative therapies for
diseases of the eye. Kala has applied its AMPPLIFY® mucus
penetrating particle Drug Delivery Technology to a corticosteroid,
loteprednol etabonate (LE), designed for ocular applications,
resulting in the October 2020 approval of EYSUVIS™ (loteprednol
etabonate ophthalmic suspension) 0.25% for the short-term (up to
two weeks) treatment of signs and symptoms of dry eye disease and
the January 2019 launch of INVELTYS® (loteprednol etabonate
ophthalmic suspension) 1% for the treatment of post-operative
inflammation and pain following ocular surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210104005019/en/
Investor Contacts: Loraine Spreen
loraine.spreen@kalarx.com 857-277-4842
Hannah Deresiewicz hannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024